Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | UBE2N | P61088 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3239986 | 0.84 | NPSR1 (0.52) | NPSR1ADORA3P2RX3ALDH1A1LMNA | |
| SCHEMBL14016195 | 0.81 | ALDH1A1 (0.53) | ADORA3ALDH1A1LMNAADORA2AADORA2B | |
| SCHEMBL1061386 | 0.79 | ALDH1A1 (0.51) | NPSR1ALDH1A1LMNAMAPTADORA2A | |
| SCHEMBL4186443 | 0.79 | SMN1; SMN2 (0.43) | ADORA3P2RX3ALDH1A1MAPTADORA2A | |
| SCHEMBL3977468 | 0.79 | SMN1; SMN2 (0.48) | ADORA3ALDH1A1LMNAMAPTADORA2A | |
| Hydrochloric Acid SCHEMBL1565880 | 0.78 | ALDH1A1 (0.50) | NPSR1ALDH1A1LMNAMAPTADORA2A | |
| SCHEMBL3240884 | 0.77 | HPGD (0.54) | NPSR1ADORA3P2RX3ADORA2A | |
| SCHEMBL9402377 | 0.77 | ADORA2B (0.52) | NPSR1ALDH1A1LMNAADORA2AADORA2B | |
| SCHEMBL3241382 | 0.75 | PDE4A (0.71) | ADORA3ADORA2AADORA2BNPC1 | |
| SCHEMBL4414242 | 0.74 | ALDH1A1 (0.56) | NPSR1ADORA3ALDH1A1LMNAADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2146996-A1 | XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT | AstraZeneca AB (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-20090088439-A1 | Diazinane Compounds | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | US | disclosed |
| US-20090088439-A1 | Diazinane Compounds | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | US | disclosed |
| US-20090088439-A1 | Diazinane Compounds | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | US | disclosed |
| WO-2009041905-A1 | PTERIDINE COMPOUNDS HAVING ACTIVITY ON THE GABA- RECEPTORS | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009041905-A1 | PTERIDINE COMPOUNDS HAVING ACTIVITY ON THE GABA- RECEPTORS | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | WO | disclosed |
| US-20090023704-A1 | Novel Compounds 737 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023704-A1 | Novel Compounds 737 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023704-A1 | Novel Compounds 737 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| WO-2008130314-A1 | XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008130314-A1 | XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088439-A1 | Diazinane Compounds | GABRB1, GRPR, GIPR | NPSR1 48/4885ADORA3 322/4885P2RX3 156/4885 |
| US-20090023704-A1 | Novel Compounds 737 | GRPR, GABRB1, GABBR1 | NPSR1 47/4885ADORA3 177/4885P2RX3 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.